Michael Kragh

2.5k total citations
51 papers, 1.4k citations indexed

About

Michael Kragh is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging and Molecular Biology. According to data from OpenAlex, Michael Kragh has authored 51 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Oncology, 23 papers in Radiology, Nuclear Medicine and Imaging and 20 papers in Molecular Biology. Recurrent topics in Michael Kragh's work include HER2/EGFR in Cancer Research (19 papers), Monoclonal and Polyclonal Antibodies Research (19 papers) and Lung Cancer Treatments and Mutations (15 papers). Michael Kragh is often cited by papers focused on HER2/EGFR in Cancer Research (19 papers), Monoclonal and Polyclonal Antibodies Research (19 papers) and Lung Cancer Treatments and Mutations (15 papers). Michael Kragh collaborates with scholars based in Denmark, United States and Spain. Michael Kragh's co-authors include Mikkel W. Pedersen, Helle J. Jacobsen, Ivan D. Horak, Klaus Koefoed, Johan Lantto, Paul E.G. Kristjansen, John S. Haurum, Adam Hey, Thomas T. Poulsen and Charles Pyke and has published in prestigious journals such as Journal of Clinical Oncology, Nature Reviews Drug Discovery and JNCI Journal of the National Cancer Institute.

In The Last Decade

Michael Kragh

50 papers receiving 1.3k citations

Peers

Countries citing papers authored by Michael Kragh

Since Specialization

Citations

This map shows the geographic impact of Michael Kragh's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Kragh with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Kragh more than expected).

Fields of papers citing papers by Michael Kragh

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Kragh. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Kragh. The network helps show where Michael Kragh may publish in the future.

Co-authorship network of co-authors of Michael Kragh

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Kragh. A scholar is included among the top collaborators of Michael Kragh based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Kragh. Michael Kragh is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Targeting of EGFR by a combination of antibodies mediates unconventional EGFR trafficking and degradation 2020 ·Scientific Reports ·Sylwia Jones, Peter King, Costin N. Antonescu, Michael G. Sugiyama, Amandeep Bhamra, Silvia Šurinová, Nicos Angelopoulos, Michael Kragh, Mikkel W. Pedersen, John A. Hartley, Clare E. Futter, Daniel Hochhauser	24
2	Sym021, a promising anti-PD1 clinical candidate antibody derived from a new chicken antibody discovery platform 2019 ·mAbs ·Torben Gjetting, Monika Gad, Camilla Fröhlich, Trine Lindsted, Maria C. Melander, Vikram Bhatia, Michael M. Grandal, Nikolaj Dietrich, Franziska Uhlenbrock, Gunther R. Galler, Magnus Strandh, Johan Lantto, Thomas Bouquin, Ivan D. Horak, Michael Kragh, Mikkel W. Pedersen, Klaus Koefoed	25
3	HER-Family Ligands Promote Acquired Resistance to Trastuzumab in Gastric Cancer 2019 ·Molecular Cancer Therapeutics ·(unknown), Francisco Javier Sánchez-Martín, Oriol Arpí, Laura Visa, Mar Iglesias, Sílvia Menéndez, (unknown), Alba Dalmases, Sergi Clavé, Mariona Gelabert‐Baldrich, Thomas T. Poulsen, Michael Kragh, Beatríz Bellosillo, Joan Albanell, Ana Rovira, Clara Montagut	42
4	Population pharmacokinetics and covariate analysis of Sym004, an antibody mixture against the epidermal growth factor receptor, in subjects with metastatic colorectal cancer and other solid tumors 2019 ·Journal of Pharmacokinetics and Pharmacodynamics ·(unknown), Rik C. Schoemaker, (unknown), (unknown), Clara Montagut, Scott Kopetz, Josep Tabernero, Michael Kragh, Janet R. Wade	3
5	Acquired Resistance to a MET Antibody In Vivo Can Be Overcome by the MET Antibody Mixture Sym015 2018 ·Molecular Cancer Therapeutics ·(unknown), Valerie Calvert, Shruti Rao, Simina M. Boca, Subha Madhavan, Ivan D. Horak, Andreas Kjær, Emanuel F. Petricoin, Michael Kragh, Thomas T. Poulsen	9
6	Sym004-induced EGFR elimination is associated with profound anti-tumor activity in EGFRvIII patient-derived glioblastoma models 2018 ·Journal of Neuro-Oncology ·Stephen T. Keir, Vidyalakshmi Chandramohan, (unknown), Michael M. Grandal, Maria C. Melander, Mikkel W. Pedersen, Ivan D. Horak, Michael Kragh, Annick Desjardins, Henry S. Friedman, Darell D. Bigner	7
7	Sym015: A Highly Efficacious Antibody Mixture against MET -Amplified Tumors 2017 ·Clinical Cancer Research ·Thomas T. Poulsen, Michael M. Grandal, (unknown), (unknown), (unknown), Klaus Koefoed, Trine Lindsted, Camilla Fröhlich, (unknown), Karsten W. Eriksen, Anna Dahlman, Helle J. Jacobsen, Thomas Bouquin, Mikkel W. Pedersen, Ivan D. Horak, Johan Lantto, Michael Kragh	42
8	Simultaneous Targeting of Two Distinct Epitopes on MET Effectively Inhibits MET- and HGF-Driven Tumor Growth by Multiple Mechanisms 2017 ·Molecular Cancer Therapeutics ·Michael M. Grandal, (unknown), Thomas T. Poulsen, Klaus Koefoed, Anna Dahlman, Gunther R. Galler, Paolo Conrotto, Sara Collins, Karsten W. Eriksen, Dafna Kaufman, George F. Vande Woude, Helle J. Jacobsen, Ivan D. Horak, Michael Kragh, Johan Lantto, Thomas Bouquin, Morag Park, Mikkel W. Pedersen	23
9	Genotyping circulating tumor DNA identifies metastatic colorectal cancer (mCRC) patients highly sensitive to Sym004 2017 ·Annals of Oncology ·(unknown), Alberto Bardelli, Thomas T. Poulsen, Rodrigo Dienstmann, Michael Kragh, Scott Kopetz, Klaus Koefoed, Fortunato Ciardiello, (unknown), Joana Vidal, Jenifer Clausell-Tormos, Giulia Siravegna, Trine Lindsted, Mikkel W. Pedersen, Giuseppe Rospo, (unknown), Paul I. Nadler, Ivan D. Horak, Josep Tabernero	1
10	Efficacy and safety of Sym004 in refractory metastatic colorectal cancer with acquired resistance to anti-EGFR therapy: Results of a randomized phase II study (RP2S) 2017 ·Annals of Oncology ·Josep Tabernero, Fortunato Ciardiello, Clara Montagut, Chunming Ding, Scott Kopetz, Thomas T. Poulsen, Alberto Bardelli, Lucjan Wyrwicz, Antonio Cubillo, Cristina Santos, (unknown), Vittorina Zagonel, Jaafar Bennouna, Salvatore Siena, Alfredo Falcone, Marta Benavent, (unknown), Michael Kragh, Ivan D. Horak, Mikhail Dvorkin	2
11	Cetuximab Resistance in Squamous Carcinomas of the Upper Aerodigestive Tract Is Driven by Receptor Tyrosine Kinase Plasticity: Potential for mAb Mixtures 2016 ·Molecular Cancer Therapeutics ·(unknown), Trine Lindsted, Camilla Fröhlich, Jesper V. Olsen, Ivan D. Horak, Michael Kragh, Mikkel W. Pedersen	15
12	Pan-HER, an Antibody Mixture Simultaneously Targeting EGFR, HER2, and HER3, Effectively Overcomes Tumor Heterogeneity and Plasticity 2015 ·Clinical Cancer Research ·Helle J. Jacobsen, Thomas T. Poulsen, Anna Dahlman, (unknown), Klaus Koefoed, Jette W. Sen, Dietmar Weilguny, Bolette Bjerregaard, (unknown), Ivan D. Horak, Mikkel W. Pedersen, Michael Kragh, Johan Lantto	71
13	Safety and Activity of the First-in-Class Sym004 Anti-EGFR Antibody Mixture in Patients with Refractory Colorectal Cancer 2015 ·Cancer Discovery ·Rodrigo Dienstmann, Amita Patnaik, Rocio García‐Carbonero, Andrés Cervantes, Marta Benavent, Susana Roselló, Bastiaan B.J. Tops, Rachel S. van der Post, Guillem Argilés, (unknown), (unknown), (unknown), Mikkel W. Pedersen, Michael Kragh, Ivan D. Horak, Stephan Braun, Eric Van Cutsem, Anthony W. Tolcher, Josep Tabernero	58
14	Targeting Three Distinct HER2 Domains with a Recombinant Antibody Mixture Overcomes Trastuzumab Resistance 2015 ·Molecular Cancer Therapeutics ·Mikkel W. Pedersen, Helle J. Jacobsen, Klaus Koefoed, Anna Dahlman, (unknown), Thomas T. Poulsen, Per‐Johan Meijer, Lars S. Nielsen, Ivan D. Horak, Johan Lantto, Michael Kragh	42
15	Pan-HER Inhibitor Augments Radiation Response in Human Lung and Head and Neck Cancer Models 2015 ·Clinical Cancer Research ·David M. Francis, Shyhmin Huang, Eric A. Armstrong, Lauryn R. Werner, Craig R. Hullett, Chunrong Li, Zachary S. Morris, Adam D. Swick, Michael Kragh, Johan Lantto, Randall J. Kimple, Paul M. Harari	22
16	Sym004, a Novel Anti-EGFR Antibody Mixture, Augments Radiation Response in Human Lung and Head and Neck Cancers 2013 ·Molecular Cancer Therapeutics ·Shyhmin Huang, Chimera R. Peet, Jarob Saker, Chunrong Li, Eric A. Armstrong, Michael Kragh, Mikkel W. Pedersen, Paul M. Harari	12
17	Sym004: A Novel Synergistic Anti–Epidermal Growth Factor Receptor Antibody Mixture with Superior Anticancer Efficacy 2010 ·Cancer Research ·Mikkel W. Pedersen, Helle J. Jacobsen, Klaus Koefoed, Adam Hey, Charles Pyke, John S. Haurum, Michael Kragh	174
18	Acute Effects of Vascular Modifying Agents in Solid Tumors Assessed by Noninvasive Laser Doppler Flowmetry and Near Infrared Spectroscopy 2002 ·Neoplasia ·Michael Kragh, Bjørn Quistorff, Michael R. Horsman, Paul E.G. Kristjansen	14
19	Quantitative Estimates of Vascularity in Solid Tumors by Non-Invasive Near-Infrared Spectroscopy 2001 ·Neoplasia ·Michael Kragh, Bjørn Quistorff, Eva Løbner Lund, Paul E.G. Kristjansen	17
20	Cuticular Proteins from the Lobster, Homarus americanus 1997 ·Comparative Biochemistry and Physiology Part B Biochemistry and Molecular Biology ·Michael Kragh, Lars Mølbak, Svend Olav Andersen	33

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact